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Abstract
Background: Non-biological experimental error routinely occurs in microarray data collected in
different batches. It is often impossible to compare groups of samples from independent
experiments because batch effects confound true gene expression differences. Existing methods
can correct for batch effects only when samples from all biological groups are represented in every
batch.
Results: In this report we describe a generalized empirical Bayes approach to correct for cross-
experimental batch effects, allowing direct comparisons of gene expression between biological
groups from independent experiments. The proposed experimental design uses identical reference
samples in each batch in every experiment. These reference samples are from the same tissue as
the experimental samples. This design with tissue matched reference samples allows a gene-by-
gene correction to be performed using fewer arrays than currently available methods. We examine
the effects of non-biological variation within a single experiment and between experiments.
Conclusion: Batch correction has a significant impact on which genes are identified as differentially
regulated. Using this method, gene expression in the blood of patients with Duchenne Muscular
Dystrophy is shown to differ for hundreds of genes when compared to controls. The numbers of
specific genes differ depending upon whether between experiment and/or between batch
corrections are performed.
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Background
Non-biological experimental variation is commonly
observed in microarray data processed in different
batches. A batch is defined as a set of microarrays that are
processed together within a single experiment. In this
report we define an experiment as an individual study
conducted at one site at one time. An experiment often
has many samples processed in multiple batches. Differ-
ent batches are processed at different times or by different
operators. Batch effects are caused by many factors such as
the methods for RNA isolation, amplification and target
labeling, and array processing and scanning. Several
methods have been proposed that can adjust for batch
effects provided a large number of samples (> 25) are
included in each batch [1,2]. More recently, an empirical
Bayes method has been described [3] that adjusts for
batch effects even when the number of samples in each
batch is small (< 10).
The aforementioned methods can adjust for batch effects
provided that samples from each biological group are rep-
resented in every batch. The left panel of Figure 1 shows
such an experimental design. All three batches contain
samples from each of the two biological groups (disease
and control). In contrast, the experiment in the right
panel of Figure 1 is an example where it is not possible to
distinguish differences in gene expression that are due to
batch effects from those that are due to the underlying
biology. Confounding batch effects are even more of a
problem when comparing array data from experiments
conducted in different laboratories. Hence, researchers
need to generate a new set of control samples for each sep-
arate experiment. If it were possible to correct for cross-
experimental batch effects, however, a single set of patient
control samples could be compared to sets of disease sam-
ples from multiple independent experiments, saving sig-
nificant resources.
In this report we present an experimental design that
allows one to compare different biological groups drawn
from independent experiments. The feature of our experi-
mental design that allows samples to be compared even
when control and experimental samples are in completely
separate experiments is that identical replicate reference
Batch processing of microarray samples from different biological groups Figure 1
Batch processing of microarray samples from different biological groups. Examples of experimental designs that can 
be corrected for batch effects (left panel) and cannot be corrected for batch effects (right panel).BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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samples of pooled RNA are processed in each batch in
every experiment. These reference samples are pooled
RNA from the same tissue as are the disease and control
experimental samples. In our study the experimental sam-
ples and reference samples are from human blood. Only
a single reference sample is necessary to be included in
each batch. Our experimental design is illustrated in Fig-
ure 2. We demonstrate models for estimating batch effects
using the empirical Bayes approach of Johnson et al [3].
We focus on single-channel microarrays, though our
methods could easily be extended to two-channel arrays.
Results
Simulations and data analyses are used to study the prop-
erties of the proposed methods. These methods are an
extension of the empirical Bayes batch effect adjustment
proposed by Johnson et al [3].
Empirical Bayes method adjusts gene expression in the 
proper direction
We first show that the empirical Bayes method can cor-
rectly adjust for batch effects using two simulated data sets
(Figures 3 and 4). For the first simulation, we select batch
effect parameter values that lower the expression levels of
patients relative to controls (Figure 3). We show that
batch adjustment restores the fold change, leading to bet-
ter power to detect truly differentially expressed genes. In
the second simulation, we study the opposite scenario
where batch effects elevate expression levels of patients
relative to controls (Figure 4). Here, batch effects lead to
false positives in the unadjusted data. Batch adjustment
correctly (and conservatively) lowers the fold change val-
ues. In both cases, batch adjustment leads to more accu-
rate conclusions.
For the first simulation, analysis of unadjusted data iden-
tifies only 265 (44%) of truly differential expressed genes
as being differentially expressed with FDR adjusted p-
value ≤ 0.05 and fold change > 2.0. Because the batch
effects lowered the fold change values, all of the remain-
ing simulated genes had fold change values of less than
2.0 (Figure 3). However, after batch adjustment, the vast
majority of truly differentially expressed genes (528 out of
600) were identified as differentially expressed, with only
70 (0.1%) false positives. The ability of the method to cor-
rectly adjust for batch effects is further illustrated in Figure
3. This scatter plot of fold change values before and after
batch adjustment shows that the majority of simulated
expressed genes (all but 40 out of the 600 red points) are
above the diagonal line, indicating that the batch adjust-
Experimental design with reference samples Figure 2
Experimental design with reference samples. This design enables the direct comparison of different biological groups 
drawn from independent experiments that would otherwise be incomparable.BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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ment method is adjusting the gene expression values in
the proper direction. The red points in the upper left sec-
tion of the plot separated by the two vertical purple lines
correspond to the simulated expressed genes that were
recovered as differentially expressed after batch adjust-
ment.
In the second simulation, batch effects amplify the expres-
sion level differences between the two groups (Figure 4).
Not surprisingly, all 600 simulated differentially
expressed genes were declared as differentially expressed
in the unadjusted data set. An additional 189 of the
remaining genes were also identified as differentially
expressed. After batch adjustment, 472 out of the 600 true
positives were correctly identified, with only 45 false pos-
itives. This indicates that while the empirical Bayes
method may be a bit stringent, it is very effective at remov-
ing false positives. The ability of the method to correctly
adjust for batch effects is shown in Figure 4. Fold change
values are lower in the adjusted data set relative to the
unadjusted data set for all but seven of the 600 expressed
genes, again indicating that the method adjusts the fold
changes in the correct direction. The blue points in the
lower right section of the plot separated by the two vertical
purple lines are gene expression values for the simulated
unexpressed genes that were correctly removed by the
batch adjustment method (Figure 4).
Empirical Bayes method removes cross-experiment batch 
effects
We next demonstrate on our experimental data set that
the empirical Bayes method removes batch effects that
occur between experiments. In this data there are two
experiments, one that includes microarray data for four
batches of control samples processed at the University of
Cincinnati and a second that includes microarray data for
patients with muscular dystrophy processed in five
batches at UC Davis. We illustrate the successful removal
Scatter plot of fold change values before and after batch adjustment for simulated data sets Figure 3
Scatter plot of fold change values before and after batch adjustment for simulated data sets. Genes are color 
coded according to their expected difference in expression level between patients and controls. Genes with the same 
expected level of expression in patients and controls are shown in black, while those with an expected 1.0 to 2.0 fold higher 
expression level in patients are in blue, and those with a 2.1 to 3.0 fold higher expression level are in red. This simulation is 
performed for data in which the batch effects artificially lowered the fold change values.BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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of batch effects by comparing expression of differentially
expressed genes before and after adjustment for batch
effects.
For the unadjusted GCRMA-summarized expression val-
ues, a total of 527 genes are differentially expressed in
patients compared to controls. Using the expression val-
ues for these genes only, we applied agglomerative hierar-
chical clustering with Pearson correlation to the 98
samples (Figure 5). The color-coded dendrogram and the
upper color bar beneath the heat map show a clear sepa-
ration of the muscular dystrophy patients (purple) from
healthy control patients (light blue). However, the UC
Davis reference arrays (gold) and the Cincinnati reference
arrays (pink) also form separate groups. This is indicative
that for this gene list there is a substantial amount of gene
expression due to cross-experimental non-biological arti-
facts. Identical reference samples otherwise should have
similar expression values and so should instead be ran-
domly intermixed.
Using the empirical Bayes method to correct for both
within and between experiment batch effects (Model 1),
we identified 629 differentially expressed genes. Figure 6
is a clustered heat map based on these 629 genes. In the
corresponding dendrogram the reference arrays (UC
Davis is gold and Cincinnati reference samples are pink)
are mixed, suggesting that the cross-experimental batch
effects have been removed. The numbers of differentially
expressed genes between the sets of reference samples also
points to the successful removal of cross-experimental
effects. While 85 genes were differentially expressed
between the two groups of reference samples before the
data was adjusted, there were no genes differentially
expressed between UC Davis and Cincinnati reference
samples after cross-experiment batch adjustment.
Empirical Bayes method removes within-experiment batch 
effects
In this section we show that the empirical Bayes method
successfully adjusts for within-experiment batch effects
Scatter plot of fold change values before and after batch adjustment for simulated data sets Figure 4
Scatter plot of fold change values before and after batch adjustment for simulated data sets. Genes are color 
coded according to their expected difference in expression level between patients and controls. Genes with the same 
expected level of expression in patients and controls are shown in black, while those with an expected 1.0 to 2.0 fold higher 
expression level in patients are in blue, and those with a 2.1 to 3.0 fold higher expression level are in red. This simulation is 
performed for data in which the batch effects artificially increased the fold change values.BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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and that these can be of even greater magnitude than the
between-experiment batch effects.
Table 1 shows the number of genes with significant
within-experiment batch effects for the unadjusted and
adjusted data sets. The numbers of genes for which the
average gene expression in at least one batch is signifi-
cantly different from the other batches (based on a one-
way ANOVA with FDR followed by a fold change filter of
2.0) are given for each experiment. For the unadjusted
data, 527 out of 54,675 genes were differentially
expressed in at least one of the five batches processed at
UC Davis, while 48 genes were for at least one of the four
batches processed at Cincinnati. Interestingly, only three
genes are in common between the two sets. Table 1 shows
that there are comparable numbers of differentially
expressed genes in at least one batch after adjusting only
for between-experiment batch effects (Model 2). Compar-
ing these large numbers of genes with significant gene
expression in at least one batch to the number of genes
differentially expressed between sets of replicate samples
for the two experiments (85) suggests that both within-
and between-experiment batch effects are of a sizeable
magnitude in this data set.
There is one batch processed at UC Davis that clearly has
the most pronounced effects. Out of the 527 genes that
were differentially expressed in at least one batch for the
unadjusted data set, nearly all (517) were differentially
expressed in the same batch. For the remaining four
batches, the numbers of differentially expressed genes
were many fewer – ranging between 27 and 112 for the
four batches processed at UC Davis and between 4 and 28
for those processed at Cincinnati. The lower color bar
Heat map of gene expression values for differentially expressed genes in muscular dystrophy data set before  adjustment for both within- and between-experiment batch effects Figure 5
Heat map of gene expression values for differentially expressed genes in muscular dystrophy data set before 
adjustment for both within- and between-experiment batch effects. Two fold or greater increases of gene expression are 
shown in RED, and two fold or greater decreases of gene expression are shown in BLUE within the clusters. Note that the UC 
Davis reference sample group (yellow) completely separates from the Cincinnati reference sample group (pink).BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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beneath the heat map in Figure 6 (color-coded according
to batch) also points to the pronounced effects in this one
batch. The samples are interspersed for all batches except
this one (colored teal). These results clearly point to the
need for a method that is capable of removing both
within and between experimental batch effects.
The numbers of differentially expressed genes are shown
in Table 1 for the data sets adjusted for both types of batch
effects (Model 1) and for within-experiment batch effects
only (Model 3). For the data set adjusted only for within-
experiment batch effects, there are only four genes that
were differentially expressed in at least one batch for the
Heat map of gene expression values for differentially expressed genes in muscular dystrophy data set after  adjustment for both within- and between-experiment batch effects Figure 6
Heat map of gene expression values for differentially expressed genes in muscular dystrophy data set after 
adjustment for both within- and between-experiment batch effects. Two fold or greater increases of gene expression are 
shown in RED, and two fold or greater decreases of gene expression are shown in BLUE within the clusters. Note that the UC 
Davis reference sample group (yellow) is interspersed with the Cincinnati reference sample group (pink).
Table 1: Numbers of differentially expressed genes between batches within a single experiment identified using ANOVA
Adjustment Method Cincinnati UC Davis Common
None 48 527 3
t-test filter 0 (of 273) 42 (of 273) 0
EB: between experiment only 96 545 8
EB: within experiment only 0 4 0
EB: within and between experiment 0 0 0
Numbers are out of 54,675 probe sets unless otherwise specified. EB = empirical Bayes.BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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UC Davis data set and no genes for the Cincinnati data set.
These numbers show that the empirical Bayes method is
very effective at removing within-experiment batch
effects. When the data was adjusted for both types of batch
effects, there were no differentially expressed genes across
batches. Similarly, no genes were differentially expressed
between UC Davis and Cincinnati reference samples after
batch adjustment with Model 1.
Comparison of the empirical Bayes method to the t-test 
filter
In this section we illustrate the advantages that the empir-
ical Bayes method offers by comparing it to a more naïve
approach which uses a t-test to filter out genes with signif-
icant differences in expression between reference arrays in
the two experiments. Applying the t-test to the 527 genes
identified as differentially expressed between patients and
controls in the unadjusted data results in the removal of
254 genes with significant between-experiment batch
effects. Out of the remaining 273 genes, while none show
differential expression in at least one of the four batches
processed in Cincinnati, 42 show differential gene expres-
sion in at least one of the five batches processed at UC
Davis (Table 1). This is not surprising because the t-test
removes genes with between-experiment batch effects but
does not adjust for batch effects within an experiment.
Moreover, the t-test filter has the additional limitation
that it does not recover false negatives. The empirical
Bayes approach identifies many more genes because it
adjusts the values in the gene expression matrix instead of
simply removing genes from a list.
Adjusting for non-biological variation significantly alters 
lists of differentially expressed genes
Figure 7 shows the genes identified as differentially
expressed in patients versus controls for the different
methods explored in this paper: empirical Bayes adjust-
ment for within and between experiment variation
(Model 1: 629 genes), t-test filtering (273 genes), and
unadjusted data (527 genes). The relatively small number
common to all three gene lists (239 genes) illustrates the
substantial effect of correcting for batch effects. Nearly
90% (239 out of 273) of the genes identified by the t-test
filter were also identified by the empirical Bayes method,
which identifies a number of additional genes.
Figure 8 shows the genes identified as differentially
expressed in patients versus controls for the three different
empirical Bayes adjustments: Model 1 (629 genes), Model
2 (555 genes), and Model 3 (618 genes). There are 342
genes common to all three gene lists. Out of these three
methods, many more unique genes are identified when
correcting only for within experiment batch effects (187)
than there are for either of the methods that correct for
cross-experiment variation (65 and 80 unique genes).
Common Genes in lists of differentially expressed  genes for three sets of gene expression values: (1)  unadjusted, (2) t-test Filtered, and (3) Empirical Bayes  adjusted data Figure 7
Common Genes in lists of differentially expressed 
genes for three sets of gene expression values: (1) 
unadjusted, (2) t-test Filtered, and (3) Empirical Bayes 
adjusted data. There are 239 genes common to all three gene 
lists.
Common Genes in lists of differentially expressed  genes for three different empirical Bayes adjusted  data sets: (1) within experiment batch effects only, (2)  cross-experiment site effects only, and (3) both cross-exper- iment site effects and within experiment batch effects Figure 8
Common Genes in lists of differentially expressed 
genes for three different empirical Bayes adjusted 
data sets: (1) within experiment batch effects only, (2) 
cross-experiment site effects only, and (3) both cross-exper-
iment site effects and within experiment batch effects. There 
are 342 genes common to all three gene lists.BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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Since there appear to be substantial cross-experiment
batch effects in this data, it is likely that this list of 187
genes contains some false positives. Overall, our simula-
tions suggest that the gene lists for empirical Bayes
adjusted data contain fewer false positives and false nega-
tives than the unadjusted analyses.
Discussion and conclusion
In this report we have shown that with an appropriate
experimental design and statistical methods it is possible
to adjust for both within and between experiment batch
effects and hence compare gene expression values
between biological groups drawn from independent
experiments. The unique feature of our experimental
design that enables us to compare data from separate
experiments is that identical replicate reference samples of
pooled RNA (that are derived from the same tissue as are
the experimental samples) are included in each batch
within each experiment. The inclusion of the identical ref-
erence samples from the same tissue in every batch in
every experiment allows us to adjust for non-biological
variation and hence be able to distinguish differences in
gene expression due to the underlying disease biology
from those due to confounding batch effects. This
approach enables us to compare the gene expression of
samples from the two groups that would otherwise be
incomparable due to confounding batch effects. The
importance and uniqueness of this method are best
understood when viewed in the context of the other meth-
ods described below.
Several computational methods have been developed to
correct for non-biological variation. Alter et al. [1] used
Singular Value Decomposition (SVD) to adjust for non-
biological variation in yeast cell cycle data while others [4]
applied this same method to correct for batch effects in a
tumor data set. Alter et al. were able to adjust for non-bio-
logical variation by inferring that the combinations of
genes and arrays that contributed the most to the variance
correspond to non-biological artifacts. By filtering out
these combinations of genes and arrays they were able to
normalize the data and compare gene expression across
arrays from different experiments. Because SVD finds the
directions of greatest variation, this approach succeeded
because in this case, the non-biological variation was the
greatest source of variation. However, if the amount of
biological variation happened to be greater than the non-
biological variation, this approach would have likely
failed to adjust non-biological variation. This motivated
Benito et al. to apply a different approach, Distance
Weighted Discrimination (DWD), to correct for system-
atic batch effects. In DWD, instead of adjusting the data
based on the direction of maximal variation (as is done in
SVD), data is adjusted according to the direction that max-
imizes the separation between two batches. While DWD
can be applied to only two batches at a time, Benito et al.
propose adjusting for three or more batches in a stepwise
manner, adjusting the two most similar first, and then
next most similar against the previously adjusted batches.
It is unclear how successful their method is in removing
batch effects when there are more than three batches.
The Bayesian approach developed by Johnson et al [3] is
based on a location and scale (L/S) model that allows a
different mean and variance for each gene and batch (see
[5] for review). It offers the advantage of circumventing
the requirements for large sample sizes while providing
robust batch adjustments for each gene by pooling infor-
mation across genes in each batch when estimating the
model parameters. Given our limited sample size in each
batch as well as the limited number of replicate identical
reference samples in each batch, this Bayesian approach is
an appropriate choice. Since many experimental designs
share these features, we expect the approach could be
widely applicable. To fully validate the current methods,
it will be important to compare the Bayesian approach
developed by Johnson et al {3} to the current approach
on a data set where both approaches could be used.
This Bayesian approach is particularly advantageous for
the analysis of our data set which had a particularly lim-
ited number of reference samples – the minimum number
of one reference sample per batch. Because in the first step
of the parameter estimation procedure, the pooled vari-
ance for each gene is calculated across all samples, the
multiplicative batch effect (i.e. the variance) can still be
estimated even when there is only a single reference sam-
ple in each batch. However, an experimental design
would ideally include more than one reference sample per
batch as a preventative measure in case one of the refer-
ence samples was of poor quality. In this study we are able
to justify the use of a single reference sample based on the
results of an ANOVA analysis of the batch adjusted data.
The bottom row of Table 1 (which shows the numbers of
differentially expressed genes between batches within a
single experiment using ANOVA) shows that after batch
effects have been adjusted for, there are no differentially
expressed genes between batches for the disease samples,
or between batches for the healthy control samples. This
suggests that if the reference sample itself deviated from
the other reference samples, the disease samples in this
batch also deviated from the other disease samples in the
other batch in a similar manner. By adjusting using the
reference sample, the biases were correctly compensated.
In subsequent studies we are addressing the optimal
number of reference samples to include in each batch.
A related concern is that the estimate of the variance for
many genes might be unusually large relative to the differ-
ences in the batch means because there was only one ref-BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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erence sample used. In this scenario the adjustment
method would often times only add noise and reduce sen-
sitivity. It is important to note that for the observed esti-
mated parameter values in our data set, it is infrequent for
the batch variances to be large relative to the differences in
the batch means. Again, even though there is only one ref-
erence sample per batch, the variance estimate is likely sta-
bilized by the pooling of samples.
The methods described above have been applied in the
context of adjusting batch effects within a single experi-
ment. Existing methods for comparing microarray data
across independent experiments include meta-analysis
where sets of genes that are consistently differentially
expressed across multiple experiments are identified. In
this approach, statistical measures of differential expres-
sion generated from data sets derived from independent
experiments are compared instead of the gene expression
data matrices from different data sets. Rhodes et al. [6]
developed a statistical approach to compare multiple
independent microarray data sets and applied it to iden-
tify sets of consistently differentially expressed genes
across four independent prostate cancer gene data sets. In
a subsequent study [7], they applied a similar method to
identify cancer "meta-signatures" – sets of genes that are
enriched in gene lists from many cancer studies.
The meta-analysis approaches described above have been
very useful in comparing independent microarray data
sets-especially when the data sets were generated across
different platforms. However, in these methods the gene
expression data matrices for test samples from one exper-
iment are not compared to the control samples from
another experiment. In contrast, our experimental design
enables such comparisons to be made between experi-
ments using the same microarray platform and hence
offers an enormous increase in the number of different
gene expression comparisons that can be made between
data sets drawn from independent microarray studies.
This makes it possible to test many more hypotheses for
differences in gene expression. For example, suppose two
independent studies were performed, each comparing a
different disease group to healthy controls. If identical ref-
erence samples were included in each of these experi-
ments, it would be possible to directly compare gene
expression values between the two disease groups and
identify genomic signatures that distinguish one disease
group from the other in addition to the genomic signa-
tures that distinguish each disease group from the healthy
individuals.
The proposed experimental design has substantial impact
for the use of microarrays in clinical studies. Because it is
possible to compare gene expression values for disease
and control samples drawn from separate experiments, it
is possible to recycle expression data for one set of con-
trols, comparing it to disease gene expression data sets for
follow-up experiments. This would eliminate the burden
and expense of reprocessing control samples each time an
experiment is repeated. Furthermore with the ability to re-
use a single control gene expression data set, it becomes
possible to define a single standard control population for
a disease study and establish a universal reference data set
of gene expression values. This would dramatically
increase the utility of microarrays in clinical diagnostics.
Methods
Microarray Data
Gene expression was measured using Affymetrix
U133plus2 microarrays on 98 human blood samples in
two separate experiments. This research in humans was
carried out in compliance with the Helsinki Declaration.
In one experiment, 66 arrays were processed at the Univer-
sity of California at Davis (UC Davis) in six batches. Fifty-
one arrays probed independent samples from teenagers
with Duchenne Muscular Dystrophy ('patients'). The
other 15 arrays probed an identical reference sample gen-
erated at UC Davis which consists of pooled RNA isolated
from four adults ('reference'). In five of the batches proc-
essed at UC Davis one reference array was included, and
the sixth batch is composed entirely of reference arrays. In
a separate experiment conducted at the University of
Cincinnati, there were 32 arrays processed in four separate
batches with each batch including between seven and
nine arrays. 28 out of the 32 arrays probed samples from
healthy teenagers ('controls'). Four arrays (one per batch)
probed the same reference sample used at UC Davis.
Sample processing and array hybridization were per-
formed according to standard Affymetrix protocols. Probe
level data were summarized into a single expression value
for each gene on each array using GCRMA in GENE-
SPRING 7 (Agilent Technologies, http://www.chem.agi
lent.com/). Pre-processing involved non-linear back-
ground reduction utilizing probe DNA sequences, quan-
tile normalization, and summarization by median
polishing [8,9]. All of the primary expression data are
deposited in the Gene Expression Omnibus (GEO) data-
base or can be obtained from the authors upon request.
Empirical Bayes Method for Batch Adjustment
Our goal is to identify genes that are differentially
expressed in patients relative to controls.
Model Formulation: The mathematical model used in the
empirical Bayes method [3] is
Yijg = αg + Xβg + γig + δigεijg (1)BMC Genomics 2008, 9:494 http://www.biomedcentral.com/1471-2164/9/494
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where Yijg is the expression value for gene g for sample j
from batch i, αg is the overall mean, X is a design matrix,
and βg is the vector of regression coefficients correspond-
ing to X. γig measures the additive batch effect of batch i for
gene g which represents the location (mean) of the adjust-
ment for this batch and is assumed to follow a normal dis-
tribution.  δig  measures the multiplicative batch effect,
which is assumed to follow an inverse gamma distribu-
tion. The error terms, εijg, are assumed to follow a normal
distribution with expected value of zero and variance σg
2.
We employ three versions of the above model to derive
three different sets of empirical Bayes adjusted data: one
adjusted for both within and between experiment non-
biological variation, a second to adjust for only the varia-
tion that occurs between experiments, and a third to
adjust only for the within experiment batch effects. We
evaluate these three different formulations in order to
assess and compare the relative effects of adjusting for the
within and between experiment non-biological variation.
Model 1: within and between experiment effects: In Equa-
tion 1 gene g has parameters γig and δig for each of the ten
distinct batches. There are a total of three regression coef-
ficients in the vector of parameters for the biological
group covariates, βg, one that specifies whether a sample
is the reference, and two that specify disease state
(healthy, Duchenne, or non-Duchenne muscular atro-
phy).
Model 2: between experiment effects only: The model for-
mulation is the same as above except that there are only
two values for γig and δig per gene, one for each experi-
ment. In this model, each experiment is considered as one
batch and batch effects within each experiment are not
modeled.
Model 3: within experiment effects only: For the case
where the data is not adjusted for between-experiment
batch effects, the reference sample is not used and so there
are only two coefficients in the vector βg.
Parameter Estimation
The model parameters are estimated as detailed by John-
son et al [3]. This process can be summarized in three
steps. First, the genes are standardized so that they all have
similar mean and variance. This step reduced the effects of
gene-to-gene variation (due to differences in mRNA
expression levels and probe sensitivities) that would oth-
erwise bias the batch effect estimates. Standardizing
involves first estimating the model parameters αg, βg, and
γig  for each gene by least squares constraining
 The pooled variance for each gene across all
samples is
where N is the total number of samples. Then, the stand-
ardized data is
In the second step, for each gene, the batch i sample mean
is estimated as
and the batch i sample variance as
These estimates are used to estimate the parameters of the
distributions of γig and δig using the method of moments.
Then, using the parameter estimates for these two prior
distributions along with Bayes theorem, posterior distri-
butions for each γig and δig are calculated. Final estimates
for the batch effect parameters, γ*ig and δ*ig, are estimated
as the expected values of the posterior distributions. This
empirical Bayes estimation procedure allows information
from all genes to be used to estimate batch effects for each
gene, providing more stable estimates than the standard
sample mean and sample variance.
In the third step, the data is adjusted to remove batch
effects. The empirical Bayes [3] batch adjusted data is
given by
We performed the above calculations using the COMBAT
software developed by Johnson et al and written in R
http://statistics.byu.edu/johnson/ComBat. This software
features diagnostic plots that allow one to check the valid-
ity of the model assumptions as well as an alternate non-
parametric Bayesian method (in case the assumptions for
parametric formulation are invalid).
Identifying Differentially Expressed Genes
We performed unpaired two-sample t-tests in GENE-
SPRING 7 to find genes with different mean expression
between disease groups. First, subjects with muscular dys-
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ˆ ( ˆ ˆ ˆ ) σα β γ gi j g g g i g ij N
YX
2 2 1
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trophy were compared to the control subjects using unad-
justed GCRMA-summarized gene expression data. The
same t-test was repeated using the various empirical Bayes
batch adjusted gene expression values. P-values were cor-
rected for mulitple comparisons with the Benjamini-
Hochberg False Discovery Rate (FDR) technique. An FDR
corrected p-value ≤ 0.05 was considered significant, which
means that no more than 5% of the declared different
genes are expected to represent false positives. We further
filtered each of the above lists removing all genes with
average fold change < 2.0.
Differentially expressed genes between batches within
each experiment were identified using one-way ANOVA
within GENESPRING with an FDR corrected p-value
threshold of 0.05.
Naïve t-test Batch Adjustment
We compare the proposed empirical Bayes approach to a
simple method that filters out genes with significant cross-
experimental batch effects based on a t-test comparing the
15 reference arrays from UC Davis to the four reference
arrays processed at the University of Cincinnati. This t-test
filter was applied to each gene that was differentially
expressed between disease groups in the GCRMA-summa-
rized unadjusted gene expression data set. Each gene that
was found to be significantly different between experi-
ments (unadjusted p-value ≥ 0.2) was removed from the
gene list because of the ambiguity regarding the reason for
its differential expression (underlying biology versus non-
biological site-specific variation). The loose p-value
threshold of 0.2 for removing genes was chosen because
of the limited accuracy of the t-test with one of the sample
sizes only being four.
Simulations
We performed two simulations to assess the ability of the
empirical Bayes method to accurately identify differen-
tially expressed genes in the presence of confounding
batch effects. In one simulation we tested the ability of the
method to recover false negatives – genes whose differen-
tial expression is reduced due to batch effects. For the sec-
ond simulated data set, we tested the ability of the method
to remove false positives – genes whose differential
expression is elevated due to batch effects.
For each simulated data set, we generated gene expression
values for 54,675 probe sets for 28 controls, 51 patients,
and 19 identical reference samples. Model parameter val-
ues were selected to reflect trends observed in the muscu-
lar dystrophy data set. Specifically, we selected parameter
values for αg and βg to generate a set of genes with mean
fold changes between the disease and healthy samples
that range between 1.1 and 3.0 in increments of 0.1. We
simulated 60 genes with each fold change to generate (1)
600 genes with fold changes greater than 2.0 (to reflect the
approximate number of differentially expressed genes in
the real data), and (2) 600 additional genes with fold
changes below 2.0, the threshold we selected for differen-
tially expressed genes. Parameter values for αg and βg for
the remaining 53,475 genes were selected so that there are
no differences in mean expression between the two
groups. The errors, εijg, for each gene were randomly sim-
ulated from a normal distribution with mean 0 and stand-
ard deviation σg, chosen to reflect the average standard
deviation observed in the real data. Batch scale parame-
ters, δig, were also selected to reflect a typical range of
observed values.
For the first simulation, we selected γig values whose mean
for the patients is lower than that for the controls by an
amount that counter balances the average difference in
mean expression between patients and controls for truly
differentially expressed genes. For the second simulation
we selected γig values so that the mean for the patients is
higher than that for the controls by an amount that gener-
ates a difference in expression between patients and con-
trols for truly non-differentially expressed genes
equivalent to that seen in truly differentially expressed
genes. In each simulation, we identify genes declared to be
differentially expressed before and after batch adjustment
and compare the numbers of genes that are correctly and
incorrectly classified as being differentially expressed in
each case.
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